In The News,

Payer/KOL P&R Input to New Oncology Biologic Development Plan

In order to test a variety of potential TPPs with payers to define value, positioning, and clinical and economic benefits necessary to optimize P&R for a new oncology biologic – and gain payer insights on the evolving competitive landscape, including biosimilars – ADVI conducted primary research with payer informant KOLs and secondary research to augment company knowledge and develop the “right questions” and TPPs.